Hannaleena Eerola

Summary

Country: Finland

Publications

  1. ncbi BACH1 Ser919Pro variant and breast cancer risk
    Pia Vahteristo
    Department of Obstetrics, Helsinki University Central Hospital, Helsinki, Finland
    BMC Cancer 6:19. 2006
  2. ncbi Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu, 00029 HUS, Helsinki Finland
    Breast Cancer Res 10:R17. 2008
  3. ncbi Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer
    Kirsimari Aaltonen
    Department of Oncology, Helsinki University Central Hospital, P O Box 180, FI 00029 HUS, Helsinki, Finland
    Breast Cancer Res Treat 113:75-82. 2009
  4. ncbi Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Finland
    Breast Cancer Res 7:R465-9. 2005
  5. ncbi Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
    Kirsimari Aaltonen
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Clin Cancer Res 14:1976-83. 2008
  6. ncbi Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Breast Cancer Res 7:R93-100. 2005
  7. ncbi Genome-wide association study identifies novel breast cancer susceptibility loci
    Douglas F Easton
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    Nature 447:1087-93. 2007
  8. ncbi Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors
    Hrefna K Johannsdottir
    Department of Pathology, Landspitali-University Hospital, Reykjavik, Iceland
    Int J Cancer 119:1052-60. 2006
  9. ncbi BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition
    Pia Vahteristo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Eur J Hum Genet 14:167-72. 2006
  10. ncbi Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival
    Johanna Tommiska
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland
    Clin Cancer Res 11:5098-103. 2005

Collaborators

Detail Information

Publications16

  1. ncbi BACH1 Ser919Pro variant and breast cancer risk
    Pia Vahteristo
    Department of Obstetrics, Helsinki University Central Hospital, Helsinki, Finland
    BMC Cancer 6:19. 2006
    ..In this study, we aimed to evaluate whether there are BACH1 genetic variants that contribute to breast cancer risk in Finland...
  2. ncbi Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu, 00029 HUS, Helsinki Finland
    Breast Cancer Res 10:R17. 2008
    ..Finding new immunohistochemical markers that are specific to hereditary breast cancer could help us to select candidates for BRCA1/BRCA2 mutation testing and to understand the biological pathways of tumour development...
  3. ncbi Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer
    Kirsimari Aaltonen
    Department of Oncology, Helsinki University Central Hospital, P O Box 180, FI 00029 HUS, Helsinki, Finland
    Breast Cancer Res Treat 113:75-82. 2009
    ..0005). In conclusion, the findings of this study show that cyclin D1 has separate roles, and proliferation is driven by different mechanisms in ER positive and negative breast cancers...
  4. ncbi Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Finland
    Breast Cancer Res 7:R465-9. 2005
    ..In sporadic breast cancer, tumours from premenopausal patients have been shown to differ from those of postmenopausal patients, but this phenomenon has been little studied among familial patients...
  5. ncbi Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
    Kirsimari Aaltonen
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Clin Cancer Res 14:1976-83. 2008
    ..Cyclin E expression in tumors of BRCA1 or BRCA2 carriers is higher, and cyclin D1 expression lower, than in sporadic tumors. In familial non-BRCA1/2 tumors, cyclin E and cyclin D1 expression has not been studied...
  6. ncbi Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
    Hannaleena Eerola
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Breast Cancer Res 7:R93-100. 2005
    ....
  7. ncbi Genome-wide association study identifies novel breast cancer susceptibility loci
    Douglas F Easton
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    Nature 447:1087-93. 2007
    ..05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach...
  8. ncbi Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors
    Hrefna K Johannsdottir
    Department of Pathology, Landspitali-University Hospital, Reykjavik, Iceland
    Int J Cancer 119:1052-60. 2006
    ..In conclusion, our results confirm a very high prevalence of chromosome 5q alterations in BRCA1 tumors, pinpointing new regions and genes that should be further investigated...
  9. ncbi BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition
    Pia Vahteristo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Eur J Hum Genet 14:167-72. 2006
    ..These results suggest that the contribution of the BARD1 germline variants to breast cancer predisposition is very limited, and that neither Cys557Ser nor Val507Met have an effect on familial breast cancer susceptibility...
  10. ncbi Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival
    Johanna Tommiska
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland
    Clin Cancer Res 11:5098-103. 2005
    ..The p53 R72P polymorphism has been suggested to play a role in many cancers, including breast cancer. Our aim was to evaluate association of R72P with breast cancer risk as well as histopathologic features of the breast tumors and survival...
  11. ncbi No germline FH mutations in familial breast cancer patients
    Maija Kiuru
    Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, P.O. Box 63 (Haartmaninkatu 8, FIN-00014 Helsinki, Helsinki, Finland
    Eur J Hum Genet 13:506-9. 2005
    ..Most of the cases were selected based on positive family or personal history for malignancies associated with HLRCC. No mutations were found. These results show that FH is not a major predisposing gene for familial breast cancer...
  12. ncbi Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables
    Hrefna K Johannsdottir
    Department of Pathology, Landspitali-University Hospital by Hringbraut, Reykjavik, Iceland
    Anticancer Res 24:2681-7. 2004
    ..CONCLUSION: The results manifest the frequent alterations of chromosome 4 in BRCA1-associated breast tumors and indicate the location of several genes of potential importance in breast cancer development...
  13. ncbi Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
    Outi Kilpivaara
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    Int J Cancer 113:575-80. 2005
    ..02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival...
  14. ncbi CHEK2 variant I157T may be associated with increased breast cancer risk
    Outi Kilpivaara
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital HUCH, Helsinki, Finland
    Int J Cancer 111:543-7. 2004
    ..The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC...
  15. ncbi Genome-wide scanning for linkage in Finnish breast cancer families
    Pia Huusko
    Cancer Genetics Branch, NHGRI, NIH, Helsinki University, Central Hospital, Helsinki, Finland
    Eur J Hum Genet 12:98-104. 2004
    ..Both linkage and association studies are likely to be useful, particularly in other isolated populations...
  16. ncbi A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
    Pia Vahteristo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 8, FIN 00029 HUS, Helsinki, Finland
    Am J Hum Genet 71:432-8. 2002
    ....